PMVP — PMV Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1699382 ·
Last close
$1.22
Market Cap
$92.15M
52W High
$1.91
52W Low
$1.02
ADV30
434,432
Next earnings
2026-11-10
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -20,063,000 -34,372,000 111,404,000 19,994,000 54,296,000
Jun 2026 0 — -18,881,000 -18,086,000 82,068,000 12,469,000 10,568,000
Mar 2026 0 — -19,019,000 -18,038,000 96,562,000 39,130,000 8,595,000
Dec 2025 0 — -19,242,000 -18,037,000 116,562,000 37,983,000 11,850,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-69,629,000
Investing CF
$5,843,000
Financing CF
$47,440,000
CapEx
$-30,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.60
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-516,950,000
Inventory
—
Receivables
—
ST Investments
$82,566,000
EBIT TTM
$-77,205,000
Pretax Income TTM
$-88,511,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -86,206,000 -77,742,000 116,562,000 11,850,000 104,712,000 -73,577,000
Dec 2024 0 -85,448,000 -58,709,000 191,288,000 15,208,000 176,080,000 -51,282,000
Dec 2023 0 -80,132,000 -68,960,000 252,152,000 26,463,000 225,689,000 -55,657,000
Dec 2022 0 -77,040,000 -73,317,000 270,308,000 24,280,000 246,028,000 -63,760,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-75,220,000
OpCashFlow TTM
—
Assets (Latest)
$82,068,000
Forward EPS
$-0.94

Peers — same industry

TickerNameMarket CapLastDaily %
ANIX Anixa Biosciences Inc $92.82M $2.67 —
GNLX GENELUX Corp $90.49M $2.00 —
NKTX Nkarta, Inc. $89.53M $1.25 —
RTSN Retension Pharmaceuticals, Inc. $95.06M $11.41 —
NBP NovaBridge Biosciences $95.10M $0.82 —

News headlines (Yahoo Finance, 1h cache)

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-10 13:00 · Yahoo
Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
2026-11-04 13:00 · Yahoo
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
2026-10-12 14:55 · Yahoo
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
2026-10-05 12:00 · Yahoo
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
2026-09-08 12:00 · Yahoo
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
2026-09-01 13:01 · Yahoo
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
2026-09-01 03:03 · Yahoo
PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering
2026-08-31 20:50 · Yahoo
PMV Pharma Announces Proposed Public Offering of Securities
2026-08-31 20:02 · Yahoo
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
2026-08-31 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.